PSA Explained
PSA is a protein made by prostate cells. The blood test can help with screening, prostate symptoms or follow-up after cancer treatment—but the number cannot tell you by itself whether cancer is present.
What the test actually measures
The laboratory reports how much prostate-specific antigen is circulating—not why it is there.
PSA is prostate-related, not cancer-specific
Normal prostate cells make PSA, and malignant cells can make it too. Anything that changes the amount of prostate tissue or irritates that tissue may affect the blood level.
“Total PSA” is the usual first result. Free PSA and other blood or urine markers may sometimes help refine risk after an elevated result; they are not stand-alone diagnoses.
Earlier detection must be weighed against false positives, biopsy harms, overdiagnosis and unnecessary treatment.
Age, Black ancestry, family history, inherited risk variants, general health and personal priorities affect screening decisions.
After a prostate-cancer diagnosis or treatment, the expected level and meaning of a change depend on the treatment and clinical plan.
Read the result in the question it was meant to answer
There is no single PSA cutoff that cleanly separates cancer from no cancer. Use the units and reference information from your own laboratory.
Confirm before concluding
A higher-than-expected PSA raises a question; it does not identify the cause.
- Benign enlargement, prostatitis and urinary infection can raise PSA.
- A repeat test is often appropriate before biomarkers, imaging or biopsy.
- Symptoms, exam findings and individual cancer risk influence urgency.
Usually reassuring, not absolute
A result within the laboratory interval may lower concern, but it cannot guarantee that cancer is absent.
- Some medicines can lower the measured level.
- A meaningful change from baseline may still deserve discussion.
- Testing intervals should reflect the screening or monitoring plan.
Use the specialist’s target
PSA is often followed over time after surgery, radiation or other prostate-cancer care.
- Expected values differ by treatment type.
- One rise does not always prove recurrence.
- Trend, timing, imaging and the full clinical picture guide decisions.
Four context checks that can change the story
Before comparing two results, ask whether the testing conditions and prostate context were comparable.
Inflammation and procedures
Prostatitis, urinary infection, urinary retention, a recent prostate biopsy or other instrumentation may raise PSA. Ask when retesting is appropriate after the issue resolves.
Activity near the draw
Ejaculation and vigorous cycling can temporarily increase PSA. Follow your laboratory’s instructions; some sources advise avoiding these for a day or two before testing.
Medicines and hormones
Finasteride and dutasteride can lower PSA. Record testosterone therapy and every prescription or supplement. Never pause or change treatment simply to alter the test.
Method and trend
Keep the units, laboratory and reference interval. Similar conditions make trends cleaner, but PSA velocity alone should not trigger imaging or biopsy.
PSA tracking around testosterone use
In testosterone and performance communities, people often add PSA to a broader monitoring panel and compare it with urinary symptoms, dose history and prior results. See Testosterone Bloodwork Explained for the larger monitoring picture.
Get a baseline and watch the trend
Users save PSA before therapy, log testosterone dose and repeat the test with clinical guidance.
Baseline context is valuable
Professional hormone guidelines include prostate-risk discussion and PSA monitoring for selected adults considering or receiving prescribed testosterone.
PSA is not a hormone safety score
A change can reflect enlargement, inflammation, infection, testing conditions or cancer risk. Percent-free PSA and “velocity” also need clinical context.
A practical path after an unexpected result
The right next step depends on whether this was screening, symptom evaluation or monitoring after treatment.
Check the context
Confirm units and the laboratory interval. Note urinary symptoms, infection, recent procedures, ejaculation, cycling, medicines, hormones and why the test was ordered.
Confirm the pattern
Compare prior full reports. For a newly elevated screening PSA, ask whether repeating the test after temporary influences resolve is appropriate before moving to secondary testing.
Choose the next question
Depending on risk, a clinician may discuss examination, urine testing, a risk calculator, free PSA or another biomarker, MRI, urology review or biopsy. None is automatic from one number.
Quick questions
Does a high PSA mean prostate cancer?
No. Cancer is one possible cause, but benign prostate enlargement, inflammation, infection and temporary influences can also raise PSA. A clinician uses repeat testing and other information to decide what the result means.
Can prostate cancer occur with a low PSA?
Yes. A lower PSA may reduce the estimated likelihood in a screening setting, but no PSA result completely rules out cancer. Symptoms, examination, risk factors and change over time still matter.
Should everyone get PSA screening?
No single schedule fits everyone, and organizations differ. Decide with a clinician based on age, health, ancestry, family or genetic risk, and how you weigh earlier detection against false positives and overdiagnosis.
Should I fast before a PSA test?
Fasting is usually not required for PSA alone, but follow the instructions for your full lab order. Ask about ejaculation, cycling, infection and recent prostate procedures because these can affect timing.
Is a fast-rising PSA automatically dangerous?
No. A change deserves context and often confirmation, but current urology guidance says PSA velocity should not be the sole reason for a secondary biomarker, imaging or biopsy.